MX362041B - Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. - Google Patents

Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.

Info

Publication number
MX362041B
MX362041B MX2016004557A MX2016004557A MX362041B MX 362041 B MX362041 B MX 362041B MX 2016004557 A MX2016004557 A MX 2016004557A MX 2016004557 A MX2016004557 A MX 2016004557A MX 362041 B MX362041 B MX 362041B
Authority
MX
Mexico
Prior art keywords
breast cancer
relates
present
bone metastasis
metastasis
Prior art date
Application number
MX2016004557A
Other languages
English (en)
Other versions
MX2016004557A (es
Inventor
Arnal Anna
Tarragona Maria
Pavlovic Milica
Planet Evarist
Gomis Roger
Original Assignee
Fundacio Inst De Recerca Biomedica Irb Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Biomedica Irb Barcelona filed Critical Fundacio Inst De Recerca Biomedica Irb Barcelona
Publication of MX2016004557A publication Critical patent/MX2016004557A/es
Publication of MX362041B publication Critical patent/MX362041B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método in vitro para predecir el riesgo de metástasis ósea de un cáncer de mama HER2+ y/o el resultado clínico de un cáncer de mama HER2+ en un sujeto que sufre del cáncer, caracterizado porque comprende: i) determinar la amplificación o número de copias del gen MAF en una muestra del sujeto; y ii) comparar la amplificación o número de copias obtenido en la etapa i) con un valor de referencia; en donde un mayor grado de amplificación o número de copias del gen con respecto al valor de referencia es indicativo de mayor riesgo de desarrollar metástasis ósea y/o resultado clínico deficiente.
MX2016004557A 2013-10-09 2014-10-07 Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. MX362041B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888984P 2013-10-09 2013-10-09
PCT/IB2014/002675 WO2015052583A2 (en) 2013-10-09 2014-10-07 Method for the prognosis and treatment of cancer metastasis

Publications (2)

Publication Number Publication Date
MX2016004557A MX2016004557A (es) 2016-07-22
MX362041B true MX362041B (es) 2019-01-07

Family

ID=52292968

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004557A MX362041B (es) 2013-10-09 2014-10-07 Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
MX2019000091A MX2019000091A (es) 2013-10-09 2016-04-08 Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019000091A MX2019000091A (es) 2013-10-09 2016-04-08 Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.

Country Status (13)

Country Link
US (1) US20170101683A1 (es)
EP (2) EP3524698A1 (es)
JP (1) JP6550045B2 (es)
KR (1) KR20160061424A (es)
CN (1) CN105980576B (es)
AU (1) AU2014333513B2 (es)
BR (1) BR112016007864A2 (es)
CA (1) CA2926894A1 (es)
DK (1) DK3055429T3 (es)
ES (1) ES2727904T3 (es)
MX (2) MX362041B (es)
TR (1) TR201907389T4 (es)
WO (1) WO2015052583A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2626431T3 (en) 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona A process for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
JP2016518815A (ja) 2013-03-15 2016-06-30 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 転移性がんの診断、予後、および処置の方法
US10793642B2 (en) 2014-12-11 2020-10-06 Inbiomotion S.L. Binding members for human c-MAF
US11596642B2 (en) * 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
CN105907886A (zh) * 2016-07-07 2016-08-31 蔡维泺 miR-124在乳腺癌骨转移疾病中的应用
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
WO2019232280A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
RU2766248C1 (ru) * 2021-01-11 2022-02-10 Федеральное государственное бюджетное научное учреждение "Томский национальной исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в первичной опухоли у больных раком молочной железы
RU2757960C1 (ru) * 2021-01-11 2021-10-25 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в метастатических лимфатических узлах у больных раком молочной железы
CN113667748B (zh) * 2021-07-19 2023-07-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用
CN114512183B (zh) * 2022-01-27 2022-09-20 北京吉因加医学检验实验室有限公司 一种预测met基因扩增或多倍体的方法及装置

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
IL126418A0 (en) 1996-04-05 1999-05-09 Salk Inst For Biological Studi Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same
EP2371962A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6982475B1 (en) 1998-03-20 2006-01-03 Mcsp, Llc Hermetic wafer scale integrated circuit structure
EE200100487A (et) 1999-03-15 2003-02-17 Axys Pharmaceuticals, Inc. Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003903540A0 (en) 2003-07-09 2003-07-24 Atdec Pty Ltd Flat panel display wall mounting system
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
WO2005029067A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
EP2435071A1 (en) * 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
DK2626431T3 (en) * 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona A process for the diagnosis, prognosis and treatment of breast cancer metastasis
US9066963B2 (en) * 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis

Also Published As

Publication number Publication date
JP6550045B2 (ja) 2019-07-24
CN105980576B (zh) 2021-07-16
BR112016007864A2 (pt) 2017-12-05
MX2016004557A (es) 2016-07-22
EP3524698A1 (en) 2019-08-14
DK3055429T3 (en) 2019-04-23
AU2014333513B2 (en) 2020-11-26
CA2926894A1 (en) 2015-04-16
JP2016539625A (ja) 2016-12-22
EP3055429B1 (en) 2019-03-27
AU2014333513A1 (en) 2016-04-28
TR201907389T4 (tr) 2019-06-21
US20170101683A1 (en) 2017-04-13
ES2727904T3 (es) 2019-10-21
WO2015052583A3 (en) 2015-07-23
CN105980576A (zh) 2016-09-28
KR20160061424A (ko) 2016-05-31
MX2019000091A (es) 2023-04-27
EP3055429A2 (en) 2016-08-17
WO2015052583A2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2013003880A (es) Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
NZ599194A (en) Methods to predict clinical outcome of cancer
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
WO2011094759A3 (en) Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
Ng et al. Non-invasive microrna signatures from the plasma of breast cancer patients reveals sensitive and specific marker for breast cancer screening
UA82125U (ru) Способ прогнозирования рефрактур у больных с ложными суставами
UA108261U (uk) Спосіб прогнозування розвитку остеопорозу
UA106708U (uk) Спосіб прогнозування зрощення перелому
AR104791A1 (es) Métodos terapéuticos y diagnósticos para el cáncer
UA99752U (uk) Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози
UA95656U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
FG Grant or registration